Nuvalent price target raised to $140 from $135 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Nuvalent (NUVL) to $140 from $135 and keeps an Overweight rating on the shares. With one new drug application under review and another planned for the first half of 2026, the company is rapidly transitioning to a revenue story, where the product launches’ ability to drive outer-year consensus estimates will be the primary determinant of share outperformance, the analyst tells investors in a research note.